Loading…
Opioid Addiction Risk Transparency Act
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 3,805 other S bills in the 115th — cohort avg 41d
Opioid Addiction Risk Transparency Act This bill amends the Federal Food, Drug, and Cosmetic Act to authorize the Food and Drug Administration to require a communication plan that is part of a medication's risk evaluation and mitigation strategy to include informing health care providers about the meaning of terms related to properties of the medication described in the labeling.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (2)
2018 · fourth_quarter · Agriculture
PRIA S1049 and antimicrobial issues (including provisions in Farm Bill)
Client expense: Not reported · Firm income: $15,000
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Government targets: Environmental Protection Agency (EPA)
2018 · fourth_quarter · Chemicals/Chemical Industry
PRIA S1049, Safer Choice, antimicrobial issues Farm Bill
Client expense: Not reported · Firm income: $15,000
Government targets: Environmental Protection Agency (EPA)
2018 · third_quarter · Chemicals/Chemical Industry
PRIA S1049, Safer Choice, antimicrobial issues Farm Bill
Client expense: Not reported · Firm income: $15,000
Government targets: Environmental Protection Agency (EPA)
2018 · third_quarter · Agriculture
PRIA S1049 and antimicrobial issues (including provisions in Farm Bill)
Client expense: Not reported · Firm income: $15,000
Government targets: Environmental Protection Agency (EPA)
2018 · second_quarter · Chemicals/Chemical Industry
PRIA S1049, Safer Choice, antimicrobial issues
Client expense: Not reported · Firm income: $15,000
Government targets: Environmental Protection Agency (EPA)
2018 · second_quarter · Agriculture
PRIA S1049 and antimicrobial issues
Client expense: Not reported · Firm income: $15,000
Government targets: Environmental Protection Agency (EPA)
2018 · first_quarter · Chemicals/Chemical Industry
PRIA S1049, Safer Choice, antimicrobial issues
Client expense: Not reported · Firm income: $15,000
Government targets: Environmental Protection Agency (EPA)
2018 · first_quarter · Agriculture
PRIA S1049 and antimicrobial issues
Client expense: Not reported · Firm income: $15,000
Government targets: Environmental Protection Agency (EPA)
2017 · fourth_quarter · Chemicals/Chemical Industry
PRIA S1049, Safer Choice, antimicrobial issues
Client expense: Not reported · Firm income: $15,000
Government targets: Environmental Protection Agency (EPA)
2017 · fourth_quarter · Agriculture
PRIA S1049 and antimicrobial issues
Client expense: Not reported · Firm income: $15,000
Government targets: Environmental Protection Agency (EPA)
2017 · third_quarter · Health Issues
Prescription drug abuse and misuse policy issues H.R. 2335 (114th Congress), provisions related to approval of abuse-deterrent opioids Abuse-deterrent opioid policy issues Pain therapy access policy issues S. 1049, provisions related to physician education on abuse-deterrent opioid products
Client expense: $143,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2017 · third_quarter · Agriculture
PRIA S1049 and antimicrobial issues
Client expense: Not reported · Firm income: $15,000
Government targets: Environmental Protection Agency (EPA)
2017 · third_quarter · Chemicals/Chemical Industry
PRIA S1049, Safer Choice, antimicrobial issues
Client expense: Not reported · Firm income: $15,000
Government targets: Environmental Protection Agency (EPA)
2017 · second_quarter · Health Issues
Prescription drug abuse and misuse policy issues H.R. 2335 (114th Congress), provisions related to approval of abuse-deterrent opioids H.R. 5127 (114th Congress), provisions related to incentives for the development of abuse-deterrent opioids H.R. 2430, provisions related to the reauthorization of the Prescription Drug User Fee Act 1st Amendment/Communications with payors/off-label policy issues Abuse-deterrent opioid policy issues Pain therapy access policy issues S. 1049, provisions related to physician education on abuse-deterrent opioid products
Client expense: $180,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE